A comparison of the IPS difference between HSG and LSG in four types (CTLA4_negative + PD-1_negative, CTLA4_positive + PD-1_negative, CTLA4_negative + PD-1_positive, CTLA4_positive + PD-1_positive) was conducted in order to determine if HRR score would predict the clinical immunotherapy effects of BC, visualized by an immunophenotype map (Fig. 8 B–E). The gene discussed is PDCD1; the disease is breast cancer.